Macrogenics Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
116,481.40
157,591.00
339,049.00
276,996.00
305,121.00
232,863
Total Accounts Receivable
2,004.00
2,935.00
1,224.00
2,764.00
13,643.00
29,583
Other Current Assets
971.70
4,211.00
2,111.00
4,187.00
3,534.00
6,678
Total Current Assets
119,457.10
164,737.00
342,384.00
283,947.00
322,298.00
269,124
Net Property, Plant & Equipment
5,035.20
6,785.00
14,841.00
17,961.00
49,983.00
56,712
Total Investments and Advances
404.90
300.00
-
7,986.00
-
-
Long-Term Note Receivable
-
525.00
-
-
-
-
Other Assets
885.20
1,539.00
2,044.00
1,369.00
1,602.00
6,294
Total Assets
125,782.40
173,886.00
359,269.00
311,263.00
373,883.00
332,130
Accounts Payable
3,169.00
1,669.00
2,967.00
3,995.00
2,451.00
Other Current Liabilities
25,652.50
25,425.00
20,321.00
23,307.00
47,304.00
Total Current Liabilities
28,821.60
27,094.00
23,288.00
27,302.00
49,755.00
Provision for Risks & Charges
-
-
2,693.00
298.00
-
Other Liabilities
18,046.30
25,506.00
19,951.00
14,912.00
24,890.00
Total Liabilities
46,867.90
52,600.00
45,932.00
42,512.00
74,645.00
Common Equity (Total)
78,914.50
121,286.00
313,337.00
268,751.00
299,238.00
Total Shareholders' Equity
78,914.50
121,286.00
313,337.00
268,751.00
299,238.00
Total Equity
78,914.50
121,286.00
313,337.00
268,751.00
299,238.00
Liabilities & Shareholders' Equity
125,782.40
173,886.00
359,269.00
311,263.00
373,883.00

About Macrogenics

View Profile
Address
9740 Medical Center Drive
Rockville Maryland 20850
United States
Employees -
Website http://www.macrogenics.com
Updated 07/08/2019
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. Its portfolio includes Margetuximab, Flotetuzumab, MGA012, MGD013, Enoblituzumab, MGD009, and Teplizumab. The company was founded by Scott E.